Wednesday, October 14, 2026

Central Banking & Policy

4 articles

Fed's Daly Signals Pause in Rate Hikes as Tariff Impact Stays Contained, Markets Rally 2%+

Fed's Daly Signals Pause in Rate Hikes as Tariff Impact Stays Contained, Markets Rally 2%+

Major U.S. equity indices surged November 11, 2025, with the S&P 500 gaining over 2% after Fed official Mary Daly indicated tariff effects remain limited to goods prices while wage growth moderates. The rally gained momentum as White House backing for a bipartisan shutdown deal removed political uncertainty. Technology and AI semiconductor stocks led gains.

ViaNews Editorial Team (Finance)•
Fed Signals Extended Rate Pause as Markets Price Just 51% Chance of June Cut

Fed Signals Extended Rate Pause as Markets Price Just 51% Chance of June Cut

The Federal Reserve is shifting toward a prolonged pause in rate cuts, with market expectations now pricing just a 51% probability of a single cut by June 2026. Chair Powell emphasized the Fed's focus on preventing tariff-driven inflation from becoming entrenched, while officials signal rates are near neutral levels.

ViaNews Editorial Team (Finance)•
Fed Holds Rates as AI Boom Papers Over a Fractured Economy

Fed Holds Rates as AI Boom Papers Over a Fractured Economy

Federal Reserve officials are signaling an extended pause on rate cuts, pointing to resilient headline growth driven largely by surging AI investment. But beneath the surface, inflation has remained stuck near 3% for close to four years, lower-income households are under severe affordability pressure, and traditional sectors are stagnating—raising hard questions about whether monetary policy is calibrated for the economy most Americans actually live in.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com